Huntsville, Alabama--(Newsfile Corp. - October 10, 2024) - Kalm Therapeutics is pleased to announce the direct investment from Innovate Alabama through the InvestAL program, made possible by the State Small Business Credit Initiative (SSBCI). This funding requires that the receiving company has raised an equivalent or higher amount of private investment. Kalm is InvestAL's largest and first life science investment to date. These funds will directly contribute to further execution toward our IND submission and starting our clinical trial in 2025.
"Innovate Alabama's InvestAL program is the first of its kind in the state, leveraging SSBCI dollars to catalyze private investment in world-changing companies like Kalm," said Innovate Alabama CEO Cynthia Crutchfield. "We are proud to invest in technology like the Kalm Patch that helps make medical care more accessible and user friendly."
The Kalm Patch utilizes "Continuous Dose" technology and delivers anti-inflammatory natural medication while protecting the skin from itching and infection. The Kalm Patch delivers its natural compound over 24 hours, providing a convenient and effective alternative to harmful topical steroids that require 3-5 applications per day.
"Kalm is honored to be chosen as one of the homegrown Alabama companies to receive investment from Innovate Alabama's InvestAL program. This funding comes as a result of in-depth diligence in a difficult fund-raising environment. We believe that we are exactly who this program exists to catalyze, life science companies that are underrepresented in Alabama's economy. We intend to utilize these funds to execute toward a regulatory approval and to expand our local team," said Kalm CEO, Chris Seibert.
Kalm Therapeutics, Inc.:
Founded in 2024, Kalm Therapeutics is a pre-clinical drug development company focused on a medicated, controlled-release patch for the non-steroidal treatment of patients with mild to moderate atopic dermatitis and psoriasis. We offer a steroid-free, natural alternative to the growing number of adults and children battling eczema.
Media Contact:
Chris Seibert
chrisseibert@kalmtherapeutics.com
www.kalmtherapeutics.com
# # #
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226198
